Gain Therapeutics hosts KOL event highlighting emerging GT-02287 Parkinson's data

Gain Therapeutics, Inc.

Virtual KOL event on Oct 14, 2025 featured Dr. Karl Kieburtz (Univ. of Rochester) and Dr. Kenneth Marek (Institute for Neurodegenerative Disorders).
Presentation focused on biomarkers, clinical endpoints, and path to disease modification for GT-02287.
GT-02287 is a GCase-targeting small molecule for Parkinson's disease; emerging data was contextualized.
Slides from the event were furnished as an exhibit; no new quantitative data or financial guidance provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.